FORT WORTH, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced that it has filed it Q3 2009 financial results and has provided a comprehensive management business update to illustrate the developments during the 2009 calendar year.
A complete copy of the Company’s Q3 2009 quarterly report that is filed with the SEC can be viewed at: http://sec.gov/Archives/edgar/data/714256/000101054909000813/wmti10q093009.htm
During the first three quarters of 2009, the Company’s efforts where focused on increasing its distribution capabilities, expanding the market visibility of its signature product CellerateRx(R) and increasing its product portfolio. The outline below provides detailed breakdown of such achievements by the Company during this period of time.
Sales Distribution Agreements
“Over the past year we have been achieving milestones to take The Company to the next level. We have recently assembled a national sales force of over 40 independent representatives in addition to our extensive international distribution channel,” stated CEO Scott Haire. “The third quarter 2009 numbers show that our efforts are beginning to pay off; our next benchmark is to become profitable in 2010 and bring earnings to the bottom line as quickly as possible, we expect to see a substantial increase in sales in the coming year as a direct result of the representatives having now completed their training.”
During the past nine months the Company has significantly expanded its distribution capabilities through the signing of the following agreements and relationships:
Independent Evidence Based Studies
“Several independently run evidence-based studies have reinforced our product’s value, and the overwhelmingly positive data can now be accessed at www.woundmanagementtechnologies.com,” said Cathy Bradshaw, President of Wound Care Innovations, the division that markets CellerateRx. “Those of us with a relative or loved one that faces a diabetic wound induced limb amputation understand the value of our Company’s unique core product which addresses a five billion dollar worldwide market.”
Below is a subset of the recent conferences and studies that have been completed:
Acquisitions
The Company has completed acquisitions that have enhanced the current and future fundamental value of the Company. Below is a list of a few of the acquisitions that have been announced and are in the process of monetization.
Technology Incubator Program
The Company announced that its BioPharma Management division expects to release news concerning its Technology Incubator Program shortly. The Company is in conversions with potential partners that can significantly advance the value of our technology relationships (including its license with VirtualHealth Technologies, Inc. for its Cifra secure healthcare platform) and other partnerships that have been previously announced.
With a synergistic focus on diabetic community the Company believes it is well positioned to provide further value to the medical community through its suite of technology relationships while further enhancing the fundamental value of the Company.
Public Company and Market Exposure Advancements
The Company is focused on increasing the market visibility and market exposure of the Company. With the achievements the Company has demonstrated over the last nine months and the goals that the company has set for 2010 we believe it would be a solid time to increase the exposure within the public markets. The increase in shareholder’s equity was a major step forward in meeting the necessary requirement for listing on a national exchange during 2010, which the Company plans to work towards.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. , with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG) http://www.celgene.com, Geron (GERN) http://www.geron.com, and Human Genome Sciences (HGSI) http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. For more information on the Company please visit http://www.woundmanagementtechnologies.com or call our shareholder information department at 954-357-0614.
“Safe Harbor” Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
CONTACT: Wound Management Technologies, Inc., +1-954-357-0614
Web site: http://www.woundmanagementtechnologies.com/
